CymaBay Therapeutics Q2 EPS $(0.01) Beats $(0.20) Estimate
Portfolio Pulse from Benzinga Newsdesk
CymaBay Therapeutics reported Q2 losses of $(0.01) per share, beating the analyst consensus estimate of $(0.20) by 95 percent. This represents a 96.77 percent increase over losses from the same period last year.
August 10, 2023 | 8:07 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
CymaBay Therapeutics reported better than expected Q2 results, with losses per share of $(0.01), beating estimates by 95%. This could potentially lead to a positive market reaction.
CymaBay Therapeutics reported a significant improvement in its Q2 earnings, beating analyst estimates by a wide margin. This is likely to be viewed positively by the market, potentially leading to an increase in the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100